semaglutide and perimenopause What Is Perimenopause? Should You Use Ozempic To

Use of GLP-1 agonists compared with bupropion-naltrexone was associated with increased risk of pancreatitis (adjusted HR, 9.09 [95% CI, 1.25-66.00]), bowel obstruction (HR, 4.22 [95% CI, 1.02-17.40]), and gastroparesis (HR, 3.67 [95% CI, 1.15-11.90) but not biliary disease (HR, 1.50 [95% CI, 0.89-2.53])

Other reported effects included: Transient fatigue Reduced appetite (therapeutically desirable in the context of weight loss) Mild injection-site reactions Altered skin sensations or cutaneous hyperesthesia (reported in ~7% of participants, mild and non-serious) Serious adverse events were rare and occurred at similar rates in the retatrutide and placebo groups (approximately 4%)

The 2014 study that got the anti-aging community interested in metformin [26:00]

Published data from the Phase 3b STRIDE trial reported that Ozempic 1 mg via subcutaneous (SC) injection once weekly improved maximum walking distance by 13% compared to placebo after 52 weeks